BRAIN Act

The BRAIN Act (HR2767), introduced on April 9, 2025, seeks to advance research in brain tumor treatment and improve awareness. The bill was immediately referred to the House Committee on Energy and Commerce, indicating the initial procedural step for legislation. A companion bill, S1330, has also been introduced in the Senate and referred to the Committee on Health, Education, Labor, and Pensions, suggesting coordinated legislative effort. This bill authorizes the creation of new grant opportunities and research networks, specifically targeting glioblastoma and cellular immunotherapy. While the bill does not appropriate specific funding amounts at this early stage, it establishes the framework for future funding allocations. The mechanism for impact would be through direct funding pipelines for research and development, which would flow to companies engaged in relevant R&D. Structural winners, should this bill progress and receive appropriations, include pharmaceutical companies with oncology and neuroscience pipelines, such as Pfizer ($PFE), Merck & Co. ($MRK), Bristol-Myers Squibb ($BMY), Regeneron Pharmaceuticals ($REGN), Vertex Pharmaceuticals ($VRTX), Gilead Sciences ($GILD), and Amgen ($AMGN). Additionally, life science tool and diagnostic companies like Illumina ($ILMN), Thermo Fisher Scientific ($TMO), and Danaher Corporation ($DHR) would benefit from increased research activity and demand for their products and services. The bill's focus on glioblastoma and cellular immunotherapy points to specific areas of growth. Recent market data shows mixed performance among these companies. Over the last 7 days, Merck ($MRK) saw a +2.33% change, Illumina ($ILMN) a +5.74% change, and Danaher ($DHR) a +4.48% change. In contrast, Bristol-Myers Squibb ($BMY) experienced a -0.67% change, Vertex Pharmaceuticals ($VRTX) a -2.00% change, and Amgen ($AMGN) a -1.84% change. Over the last 30 days, Pfizer ($PFE) was up +4.58% and Merck ($MRK) up +4.12%, while Bristol-Myers Squibb ($BMY) was down -2.32%, Vertex Pharmaceuticals ($VRTX) down -5.75%, and Amgen ($AMGN) down -6.81%. The bill is in an early legislative stage, requiring committee review, potential amendments, and votes in both chambers before it can be sent to the President. The presence of a companion bill in the Senate suggests a higher probability of eventual passage compared to a standalone House bill. Key legislative steps remaining include committee hearings, markups, and votes in both the House and Senate, followed by potential conference committee negotiations if there are differences between the House and Senate versions. The timeline for these steps is uncertain, but the bill's early stage means significant time will pass before any potential enactment.